Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevoflurane vs remimazolam for inflammatory biomarkers after third molar extraction
jRCT1031260294Not yet recruiting
- Sponsor
- Showa University Dental Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of sevoflurane and remimazolam in Impacted lower third molar (2 arms), sponsored by Showa University Dental Hospital. Primary endpoint: Change in serum IL-6 concentration from baseline to 24 hours postoperatively. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sevofluraneremimazolam
03
Conditions
Impacted lower third molar
Beyond the preview
Go deeper on jRCT1031260294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260294.